Besides, experimental studies in both elastase and calcium chloride and Ang II-induced AAA, treatment with the GLP-1 agonist (lixisenatide and sitagliptin respectively) reduced AAA development, decreased macrophage infiltration and TNFα mRNA and MMP-9 expression in the aorta (148, 149). Here, MMP9 is linked to triple-A syndrome.